CLAIMS

1. A composition comprising:

(a) botulinum neurotoxin; and

(b) non-crosslinked hyaluronic acid having an average molecular weight of 2.5 MDa to 4.5 MDa.

2. A composition according to Claim 1, in which the botulinum neurotoxin is botulinum neurotoxin type A.

3. A composition according to Claim 1 or 2, in which the polydispersity index of the non-crosslinked hyaluronic acid is from 1.1 to 4.0.

4. A composition according to Claim 1, 2 or 3, containing 2 to 4 units of botulinum neurotoxin or 20 to 40 units of botulinum neurotoxin per milligram of non-crosslinked hyaluronic acid.

5. A composition according to any preceding claim, in which the composition further comprises:

(c) a salt;

(d) optionally, a neurotoxin stabilizing agent;

(e) a crystallization inhibitor;

(f) a buffer; and/or

(g) a radical scavenging agent.

6. A composition according to any preceding claim, the composition having a dynamic viscosity from 1.5 to 4 Pa·s, when determined at 25°C and using an oscillation frequency of 1 Hz.

7. A composition according to any of Claims 1 to 6 for use in the treatment or prevention of dystonia, in which 200 to 500 units botulinum neurotoxin are to be administered.

8. A composition according to any of Claims 1 to 6 for use in the treatment or prevention of spasticity, in which 500 to 1000 units botulinum neurotoxin are to be administered.

9. Use of a composition according to any of Claims 1 to 6 in the preparation of a medicament for the treatment or prevention of dystonia, in which each dose comprises 200 to 500 units botulinum neurotoxin.

10. Use of a composition according to any of Claims 1 to 6 in the preparation of a medicament for the treatment or prevention of spasticity, in which each dose comprises 500 to 1000 units botulinum neurotoxin.

11. A composition for use according to Claim 7 or 8 or a use according to Claim 9 or 10, in which the composition remains at the site of administration for up to 24 hours after the application.

12. A composition for use according to Claim 7, 8 or 11 or a use according to Claim 9, 10 or 11, in which the botulinum neurotoxin is released within 12 hours.

13. A composition for use according to any of Claims 7, 8, 11 or 12 or a use according to any of Claims 9 to 12, in which the composition is to be administered every 4 to 9 months.

14. A cosmetic method for smoothing or preventing wrinkles of a mammal, preferably wrinkles being a consequence of extensive mimic activity, the method comprising administering a composition according to any of Claims 1 to 6.

15. A cosmetic method according to Claim 14, which the administration is repeated after 4 to 9 months.

16. A cosmetic method according to Claim 14 or 15, in which each dose of the composition comprises 40 to 50 units of botulinum neurotoxin.

17. Cosmetic use of a composition according to any of Claims 1 to 6 for smoothing or preventing wrinkles, preferably wrinkles being a consequence of mimic activity, in which the composition applied comprises 40 to 50 units of botulinum.